证券代码：301332 证券简称：德尔玛 公告编号：2025-034 （四） 2024 年 7 月 29 日，公司召开 2024 年第二次临时股东大会，审议并 通过了《关于公司〈2024 年限制性股票激励计划（草案）〉及其摘要的议案》 《关于公司〈2024 年限制性股票激励计划实施考核管理办法〉的议案》及《关 于提请股东大会授权董事会办理公司 2024 年限制性股票激励计划相关事宜的议 案》，并于 2024 年 7 月 29 日披露了《广东德尔玛科技股份有限公司关于 2024 年限制性股票激励计划内幕信息知情人买卖公司股票及其衍生品种情况的自查 报告》（公告编号：2024-039）。 广东德尔玛科技股份有限公司 关于作废 2024 年限制性股票激励计划部分已授予尚未归属 的限制性股票的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 广东德尔玛科技股份有限公司（以下简称"公司"）于 2025 年 7 月 31 日召 开了第二届董事会第十一次会议及第二届监事会第十一次会议，审议通过了《关 于作废 2024 年限制性股票激励计划部分已授予尚未归属的限制性股票的 ...

关于 2023 年限制性股票激励计划部分限制性股票回购注销 完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 证券代码：002892 证券简称：科力尔 公告编号：2025-055 科力尔电机集团股份有限公司 特别提示： 激励计划（以下简称"本激励计划"）回购注销限制性股票的数量为 121.0104 万股，占公司总股本的 0.16%，回购价格为 2.745 元/股，涉及激励对象 17 人， 回购金额共计 3,321,735.48 元。 公司办理完成上述部分限制性股票的回购注销手续。本次回购注销完成后，公司 总股本由 744,961,064 股减少至 743,750,960 股。 一、本激励计划已履行的相关审批程序 （一）2023 年 2 月 3 日，公司召开第三届董事会第七次会议，审议通过《关 于公司<2023 年限制性股票激励计划（草案）>及其摘要的议案》 《关于公司<2023 年限制性股票激励计划实施考核管理办法>的议案》《关于提请股东大会授权董 事会办理股权激励相关事宜的议案》《关于召开 2023 年第二次临时股东大会的 议案》等议案，律师事务所 ...

北京达辉律师事务所 关于广东德尔玛科技股份有限公司 第一个归属期归属条件成就及 致：广东德尔玛科技股份有限公司 北京达辉律师事务所（以下简称"本所"）是具有中国法律执业资格的律师事务所。根 据广东德尔玛科技股份有限公司（以下简称"德尔玛"、"公司"、"本公司"或"上市公 司"）与本所签订的法律顾问协议，本所担任德尔玛2024年限制性股票激励计划（以下 简称"本激励计划"）的特聘专项法律顾问，就公司本激励计划首次授予部分第一个归 属期归属条件成就（以下简称"本次归属"）及部分限制性股票作废事项（以下简称"本 次作废"）出具本法律意见书。 为出具本法律意见书，本所律师依据《公司法》《证券法》《管理办法》《上市规 则》《自律监管指南第1号》及其他适用的法律、行政法规及适用的政府部门其他规 章、规范性文件的规定，按照律师行业公认的业务标准、道德规范和勤勉尽责的精 神，本着审慎性原则及重要性原则，审阅了本激励计划的相关文件，并通过查询政府 公开信息对相关事实和资料进行了核查和验证。 本所及指派律师依据《证券法》《律师事务所从事证券法律业务管理办法》和《律师 事务所证券法律业务执业规则》等规定及本法律意见书出具日以前已经 ...

Group 1 - The board of directors of Zhejiang Yongtai Technology Co., Ltd. held its second meeting of the seventh session, where several resolutions were passed [1][2] - The first resolution approved the achievement of the conditions for the first unlock period of the 2024 restricted stock incentive plan, allowing 298 eligible participants to unlock a total of 4,454,841 shares [1][2] - The second resolution involved the repurchase and cancellation of 273,159 shares of restricted stock that were granted but not yet unlocked due to performance assessment not being fully met [2][3] Group 2 - The third resolution approved changes to the company's registered capital, reducing it from RMB 925,400,795 to RMB 925,127,636, and corresponding amendments to the company’s articles of association [3][4] - The fourth resolution announced the convening of the second extraordinary general meeting of 2025, scheduled for August 21, 2025, to discuss the board's submitted proposals [4]

Group 1 - The company held its 14th meeting of the third board of directors on July 31, 2025, with all 8 directors present, complying with relevant laws and regulations [1][2] - The board elected Mr. Xia Houjun as the representative director to execute company affairs and serve as the legal representative, with a term lasting until the end of the current board's term [1][2] - The board approved the election of members for the third audit committee, including Mr. Li Jing as the convener, ensuring a majority of independent directors, in accordance with legal requirements [2][3] Group 2 - The board approved the initial grant of restricted stock to 103 eligible participants under the 2025 Restricted Stock Incentive Plan, with a total of 2.19 million shares granted at a price of 15.64 yuan per share [2][3] - The proposal for the stock incentive plan was reviewed and approved by the company's remuneration and assessment committee prior to the board meeting [3]

Core Viewpoint - Zhejiang Fulai New Materials Co., Ltd. has approved its 2025 restricted stock incentive plan, which includes the granting of 2.19 million shares to 103 eligible participants at a price of 15.64 yuan per share [2]. Group 1: Incentive Plan Details - The incentive plan is in accordance with relevant laws and regulations, including the Company Law and Securities Law of the People's Republic of China [2]. - The first grant date for the incentive plan is set for July 31, 2025 [2]. - The plan specifies that certain individuals, such as those recognized as inappropriate candidates by the stock exchange or the China Securities Regulatory Commission (CSRC) within the last 12 months, are excluded from eligibility [2]. Group 2: Eligibility Criteria - Eligible participants must not have been subject to administrative penalties or market entry bans due to major violations in the last 12 months [2]. - Individuals who hold more than 5% of the company's shares, as well as the actual controllers and their immediate family members, are also excluded from being incentive recipients [2]. - The committee confirmed that the selected participants meet the qualifications outlined in the company's articles of association and the draft of the incentive plan [2].

Core Points - The company has approved the first grant of restricted stock under the 2025 Restricted Stock Incentive Plan, with a grant date set for July 31, 2025 [1][12] - A total of 2.19 million shares will be granted at a price of 15.64 yuan per share [1][12] - The incentive plan aims to motivate and retain key employees, with 103 core staff members selected as recipients [4][12] Decision Process and Disclosure - The decision-making process for the incentive plan has been completed, and relevant documents were disclosed to shareholders [2][12] - The remuneration and assessment committee has verified the list of recipients and confirmed no objections were raised during the public notice period [2][12] Grant Conditions - The board confirmed that all conditions for granting the restricted stock have been met, including compliance with regulatory requirements [3][4] - The recipients of the restricted stock are not allowed to sell or transfer the shares before the lifting of restrictions [5][6] Vesting Schedule - The vesting of the restricted stock will occur in three phases over a period of 48 months, with specific performance targets set for each phase [6][7][9] - The performance targets for the first three years are set at a minimum of 60 million yuan, 80 million yuan, and 100 million yuan in net profit, respectively [9][10] Financial Impact - The grant of restricted stock is expected to have a minor impact on the company's financial status, with costs to be amortized over the relevant periods [10][11] - The funds raised from the stock grant will be used to supplement the company's working capital [11] Legal Compliance - The legal opinion confirms that all necessary approvals and authorizations for the stock grant have been obtained, ensuring compliance with relevant regulations [12][13]

东吴证券7月31日发布研报称，给予安克创新（300866.SZ，最新价：126.9元）买入评级。评级理由主 要包括：1）本次激励计划授予股份数占总股本1%，首次授予激励范围涵盖608名骨干员工；2）授予价 格无折让，彰显公司对未来前景的信心；3）激励目标：年化收入或扣非净利增速约10%；4）激励成本 较低：根据公司激励草案测算。风险提示：股权激励计划落地尚存不确定性，地缘及关税影响，新品发 展低于预期等。 （文章来源：每日经济新闻） ...

证券研究报告·公司点评报告·消费电子 安克创新（300866） 拟发布限制性股票激励计划，授予价格无折 让彰显公司信心 买入（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 17,507 | 24,710 | 33,013 | 41,996 | 52,128 | | 同比（%） | 22.85 | 41.14 | 33.60 | 27.21 | 24.13 | | 归母净利润（百万元） | 1,615 | 2,114 | 2,458 | 3,351 | 4,217 | | 同比（%） | 41.22 | 30.93 | 16.25 | 36.34 | 25.85 | | EPS-最新摊薄（元/股） | 3.04 | 3.98 | 4.62 | 6.30 | 7.93 | | P/E（现价&最新摊薄） | 41.77 | 31.90 | 27.44 | 20.13 | 15.99 | [Table_Tag] [Table ...

Core Viewpoint - Huakang Clean (301235.SZ) reported significant growth in its 2025 semi-annual results, with a 50.73% increase in revenue and a turnaround in net profit, indicating strong operational performance and effective order acquisition strategies [1][2]. Financial Performance - In the first half of 2025, the company achieved a revenue of 835 million yuan, a year-on-year increase of 50.73% [1][2]. - The net profit attributable to shareholders reached 18.68 million yuan, marking a substantial increase of 273.48% compared to the previous year [1][2]. - The basic earnings per share were 0.19 yuan, with a net profit margin of 2.40%, up 4.34 percentage points from the same period last year [2]. Business Development - Huakang Clean has transitioned from a focus on medical equipment to providing integrated cleanroom solutions across three strategic areas: medical specialty, laboratory, and electronic cleanrooms [2]. - The company reported a total order backlog of 3.827 billion yuan as of June 30, 2025, with significant contributions from medical specialty orders (2.537 billion yuan), laboratory orders (774 million yuan), and electronic cleanroom orders (121 million yuan) [3]. Incentive Plan - Alongside the semi-annual report, Huakang Clean announced a restricted stock incentive plan, proposing to grant 5.2358 million shares to 204 key personnel, representing 4.96% of the total share capital [4]. - The grant price is set at 18 yuan per share, with a maximum vesting period of 36 months [4]. - The plan aims to enhance corporate governance and retain core talent, with a performance target of achieving a net profit of no less than 100 million yuan for 2025 [4].